STOCK TITAN

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC).

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

NEW YORK, NY / ACCESSWIRE / January 20, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC).

About China SXT Pharmaceuticals, Inc.

Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use.

For more information, please visit www.sxtchina.com

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short ...

About Aegis Capital Corporation

Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.

For more information about this offering or Investment Banking Services please email Banking@aegiscap.com or call (212) 813-1010.

Shape, logoDescription automatically generated

www.aegiscapcorp.com

Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC. Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.

SOURCE: Aegis Capital Corp.



View source version on accesswire.com:
https://www.accesswire.com/684835/Aegis-Capital-Corp-Acted-as-Sole-Bookrunner-on-a-41-Million-Underwritten-Public-Offering-of-Ordinary-Shares-Inclusive-of-the-Over-Allotment-for-China-SXT-Pharmaceuticals-Inc-NASDAQ-SXTC

China SXT Pharmaceuticals, Inc. Ordinary Shares

NASDAQ:SXTC

SXTC Rankings

SXTC Latest News

SXTC Stock Data

593.81k
581.58k
22.01%
1.62%
4.64%
All Other Miscellaneous Chemical Product and Preparation Manufacturing
Manufacturing
Link
United States of America
Po Box 905

About SXTC

china sxt pharmaceuticals, inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional chinese medicine piece tablets (tcmp) in china. it offers advanced, fine, and regular tcmp products, such as chenxiang, sanqifen, hongqi, sumu, jiangxiang, cuyanhusuo, xiatianwu, luxuejing, xuejie, chaosuanzaoren, hongqumi, chuanbeimu, huangshukuihua, wuweizi, dingxiang, renshen, qingguo, juemingzi, and sharen. the company provides its products under the suxuantang, hui chun tang, and tong ren tang brands. as of may 2, 2020, it served 116 pharmaceutical companies, 56 pharmacies, and 76 hospitals. the company was founded in 2005 and is based in taizhou, china.